-
Teva, Royalty ink $500M autoimmune drug deal
12 Jan 2026 07:37 GMT
… begin in 2026. Pending trial results, Royalty Pharma may … treatment is currently in Phase 1b trials for vitiligo and Phase 2a trials … late-stage drug development. Teva, a global pharmaceutical company based … as clinical assets such as olanzapine LAI, DARI (ICS…
-
<![CDATA[December in Review: Updates on the Psychiatric Treatment Pipeline]]>
30 Dec 2025 15:40 GMT
… , MD, the chief medical officer of Incannex, to … California. Phase 1 trials on the drug showed a favorable … treatment-resistant schizophrenia.
Teva Pharmaceuticals has submitted a New Drug … US Food and Drug Administration for olanzapine extended-release …
-
<![CDATA[Extended‑release olanzapine may improve adherence to treatments for schizophrenia]]>
13 Dec 2025 02:37 GMT
… submitted a new drug application (NDA) to the FDA for a … in schizophrenia care.
Teva Pharmaceuticals announced on Dec. 9 … clinicians more options. Every medication has its own pharmacological effects … ;s olanzapine LAI will be another tool in the treatment of …
-
<![CDATA[NDA Submission: Olanzapine Extended-Release Injectable Suspension for Treatment of Schizophrenia]]>
09 Dec 2025 17:36 GMT
… from the phase 3 SOLARIS trial, including week 56 results studying … R&D and chief medical officer at Teva. “Teva is … oral treatment options.”
References
1. Teva Pharmaceuticals submits New Drug Application to FDA for olanzapine …
-
<![CDATA[Teva Pharmaceuticals Submits NDA on TEV-‘749 for Schizophrenia to the FDA]]>
09 Dec 2025 17:54 GMT
… delivery of olanzapine, a foundational treatment for schizophrenia, … controlled 56-week SOLARIS trial assessing the efficacy, … or tolerates all medicines,” SOLARIS investigator Andrew … -pharmaceuticals-submits-new-drug-application-to-fda-for-olanzapine-extended …
-
Teva Pharmaceuticals Submits New Drug Application to FDA for Olanzapine Extended-Release Injectable Suspension (TEV-'749) for the Once-Monthly Treatment of Schizophrenia in Adults
09 Dec 2025 13:00 GMT
… S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE … Food and Drug Administration (FDA) for olanzapine extended-release … injectable suspension (TEV-'749) for the treatment … amp;D and Chief Medical Officer at Teva. …
-
Semaglutide helps manage metabolic side effects of antipsychotic drugs
10 Dec 2025 00:45 GMT
… medications. A randomized trial demonstrated that patients taking this drug … not respond to other treatments.
Doctors face a difficult … had started treatment with either clozapine or olanzapine within … greater benefits. Longer trials would be necessary to …
-
Medincell Files for FDA Approval of Olanzapine LAI
09 Dec 2025 18:46 GMT
… its partner, Teva Pharmaceuticals, has submitted a New Drug Application (NDA) to … and Drug Administration (FDA) for Olanzapine LAI, intended for the monthly treatment of schizophrenia …
-
Olanzapine Market Trends and Analysis by Application, Vertical, Region, and Segment Forecast to 2029
08 Dec 2025 16:15 GMT
… treatment options, including olanzapine. This atypical antipsychotic drug … Pharmaceutical, a pharmaceutical … Olanzapine + Fluoxetine, Olanzapine + Other Antipsychotics, Olanzapine + Mood Stabilizers, Olanzapine + Antidepressants
View the full olanzapine …
-
The Ketogenic Diet: An Anti-Inflammatory Treatment for Schizophrenia?
30 Nov 2025 17:36 GMT
… numerous studies, clinical trials and Cochrane systematic reviews … , independent of antipsychotic medication effects.54 Studies indicate … evidence and recommendations. Drugs. 2021;81(11):1273 … Z. Ketogenic diet and olanzapine treatment alone and in combination …